Trials / Completed
CompletedNCT00540943
Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer
Phase I Study of Safety and Pharmacokinetics of Pazopanib in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Subjects will be entered into cohorts of 3 for the dose escalation phase so that the maximum tolerated dose can be determined. 18 additional patients will be recruited once the maximum tolerated dose (MTD) is determined for disease assessment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pazopanib | Pazopanib is a potent, multi-targeted tyrosine kinase inhibitor of VEGFR-1, -2, -3, PDGFR-alpha and -beta and c-kit. |
| DRUG | Cetuximab | Cetuximab will be supplied as a single-use 50 milliliter vial containing 100 micrograms of cetuximab as a sterile, preservative-free, injectable liquid at a concentration of 2 milligram per milliliter in phosphate. buffered saline |
| DRUG | Irinotecan | Irinotecan hydrochloride trihydrate is an antineoplastic agent of the topoisomerase I inhibitor class. |
Timeline
- Start date
- 2007-07-13
- Primary completion
- 2010-05-03
- Completion
- 2010-05-03
- First posted
- 2007-10-08
- Last updated
- 2017-11-29
Locations
2 sites across 1 country: France
Source: ClinicalTrials.gov record NCT00540943. Inclusion in this directory is not an endorsement.